Randomized trial demonstrates efficient synthesis of chiral phosphinamidates, suggesting broad application in drug discovery.
P ‐stereogenic phosphinamidates are highly pivotal structural motifs in drug discovery and the design of chiral ligands. Despite their utility, catalytic enantioselective access to these compounds remains a formidable challenge. Herein, we report the first nickel‐catalyzed asymmetric hydrophosphinamidation of alkynes. This protocol enables the highly efficient and enantioselective synthesis of structurally diverse alkenyl phosphinamidates, accommodating a wide array of both N, N ‐dialkyl and N ‐alkyl substituted H ‐phosphinamides. Notably, the resulting products exhibit orthogonal reactivities at four distinct sites, serving as a powerful and universal platform for the divergent synthesis of complex P ‐stereogenic architectures.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: